3,4,5-trimethoxyphenoxyacetic acid | 65876-10-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4,5-trimethoxyphenoxyacetic acid
• 英文别名: 2-(3,4,5-trimethoxyphenoxy)acetic Acid
• CAS: 65876-10-0
• 化学式: C₁₁H₁₄O₆
• 分子量: 242.229
• InChiKey: DUUIKSNOGTVREZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3,4,5-trimethoxyphenoxyacetic acid 在 aluminum oxide 、 PPA 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 生成 2-[1-[3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-meth-(Z)-ylidene]-4,5,6-trimethoxy-benzofuran-3-one
  参考文献：
  名称：

  The total synthesis of an aurone isolated from Uvaria hamiltonii : aurones and flavones as anticancer agents

  摘要：

  The naturally occurring aurone 1, isolated from Uvaria hamiltonii, and a series of aurones analogues based structurally on known tubulin binding agents were prepared and evaluated for anticancer activity. Aurone 20 was the most active (IC50 K562 50 nM) and caused significant G(2)/M cell-cycle arrest. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.07.003
• 作为产物：
  描述：

  3,4,5-三甲氧基苯酚 在 水 、 potassium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 3,4,5-trimethoxyphenoxyacetic acid
  参考文献：
  名称：

  无催化剂光氧化还原加成环化：利用芳基乙酸和马来酰亚胺之间的天然协同作用

  摘要：

  当在马来酰亚胺存在下用 UVA 照射时，适当官能化的羧酸会发生以前未知的光氧化还原反应。发现马来酰亚胺协同作用作为产生自由基的光氧化剂和作为自由基受体，不需要外在的光氧化还原催化剂。在 13 次制备性光解中获得了中等至极好的产率的产物色基吡咯二酮、硫代色基吡咯二酮和吡咯并喹啉二酮衍生物。原位核磁共振光谱用于研究每个反应。监测反应物衰变和产物堆积，从而绘制反应曲线。一种似是而非的机制，即光激发的马来酰亚胺充当氧化剂以产生自由基离子对，已被假设并得到 UV/Vis 的支持。光谱和 DFT 计算。

  DOI：

  10.1002/chem.201304929

文献信息

• Catalyst-Free Photoredox Addition-Cyclisations: Exploitation of Natural Synergy between Aryl Acetic Acids and Maleimide
  作者：David W. Manley、Andrew Mills、Christopher O'Rourke、Alexandra M. Z. Slawin、John C. Walton

  DOI：10.1002/chem.201304929

  日期：2014.4.25

  Suitably functionalised carboxylic acids undergo a previously unknown photoredox reaction when irradiated with UVA in the presence of maleimide. Maleimide was found to synergistically act as a radical generating photoxidant and as a radical acceptor, negating the need for an extrinsic photoredox catalyst. Modest to excellent yields of the product chromenopyrroledione, thiochromenopyrroledione and

  当在马来酰亚胺存在下用 UVA 照射时，适当官能化的羧酸会发生以前未知的光氧化还原反应。发现马来酰亚胺协同作用作为产生自由基的光氧化剂和作为自由基受体，不需要外在的光氧化还原催化剂。在 13 次制备性光解中获得了中等至极好的产率的产物色基吡咯二酮、硫代色基吡咯二酮和吡咯并喹啉二酮衍生物。原位核磁共振光谱用于研究每个反应。监测反应物衰变和产物堆积，从而绘制反应曲线。一种似是而非的机制，即光激发的马来酰亚胺充当氧化剂以产生自由基离子对，已被假设并得到 UV/Vis 的支持。光谱和 DFT 计算。
• Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids
  作者：D. J. Abraham、P. E. Kennedy、A. S. Mehanna、D. C. Patwa、F. L. Williams

  DOI：10.1021/jm00374a006

  日期：1984.8

  small molecules, benzyloxy and phenoxy acids, as potent inhibitors of hemoglobin S (HbS) gelation. Structural modifications with a large number of each class confirm our earlier work that the highest activity is observed with compounds that contain dihalogenated aromatic rings with attached polar side chains. We have also found a halogenated aromatic malonic acid derivative to be quite active. Compounds

  在本文中，我们进一步确立了两类小分子，即苄氧基和苯氧基酸的活性，它们是血红蛋白S（HbS）凝胶化的有效抑制剂。每个类别都有大量结构修饰，这证实了我们较早的工作，即发现含有带有连接的极性侧链的二卤代芳环的化合物具有最高的活性。我们还发现卤代芳族丙二酸衍生物非常活泼。将本文报道的化合物与我们实验室研究的其他抗胶凝剂进行了比较。关于四种衍生物的抗胶凝活性和结合位点及其对血红蛋白（Hb）功能的变构机制的影响进行了评论。
• Piperidine derivatives and their use as anti-inflammatory agents
  申请人：Arnaiz O. Damian

  公开号：US20060167044A1

  公开（公告）日：2006-07-27

  Piperidine derivatives of the following formulae I and II: and their pharmaceutically acceptable salts, which are functional antagonists of the CC chemokine receptor CCR1 and are thus useful as anti-inflammatory agents, a pharmaceutical compositions containing said piperidine derivatives or their pharmaceutically acceptable salts, and methods of their use.

  以下公式I和II的哌啶衍生物及其药学上可接受的盐，它们是CC趋化因子受体CCR1的功能性拮抗剂，因此可用作抗炎剂。药物组合物包含上述哌啶衍生物或其药学上可接受的盐，并且使用它们的方法。
• Regioselective synthesis and cytotoxicities of camptothecin derivatives modified at the 7-, 10- and 20-positions
  作者：Xian-dao Pan、Rui Han、Piao-yang Sun

  DOI：10.1016/j.bmcl.2003.08.012

  日期：2003.11

  A series of 7-acyloxymethylcamptothecin and 20-O-acyl-7-acyloxymethyleamptothecin derivatives were regioselectively prepared on different solvents. 7-Acyloxymethylcamptothecins possess more efficacy than 20-O-acyl-7-acyloxymethylcamptothecins against six human cancer cell lines in vitro. (C) 2003 Elsevier Ltd. All rights reserved.
• Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents
  作者：Thomas F. Greene、Shu Wang、Lisa M. Greene、Seema M. Nathwani、Jade K. Pollock、Azizah M. Malebari、Thomas McCabe、Brendan Twamley、Niamh M. O’Boyle、Daniela M. Zisterer、Mary J. Meegan

  DOI：10.1021/acs.jmedchem.5b01086

  日期：2016.1.14

  Structure-activity relationships for a series of 3-phenoxy-1,4-diarylazetidin-2-ones were investigated, leading to the discovery of a number of potent antiproliferative compounds, including trans-4-(3-hydroxy-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (78b) and trans-4-(3-amino-4-methoxyphenyl)-3-phenoxy-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (90b). X-ray crystallography studies indicate the potential importance of the torsional angle between the 1-phenyl A ring and 4-phenyl B ring for potent antiproliferative activity and that a trans configuration between the 3-phenoxy and 4-phenyl rings is generally optimal. These compounds displayed IC50 values of 38 and 19 nM, respectively, in MCF-7 breast cancer cells, inhibited the polymerization of isolated tubulin in vitro, disrupted the microtubular structure in MCF-7 cells as visualized by confocal microscopy, and caused G(2)/M arrest and apoptosis. Compound 90b possessed a mean GI50 value of 22 nM in the NCI60 cell line screen, displayed minimal cytotoxicity, and was shown to interact at the colchicine-binding site on beta-tubulin. Phosphate and amino acid prodrugs of both 78b and 90b were synthesized, of which the alanine amide 102b retained potency and is a promising candidate for further clinical development.